Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2017-03-08 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve final results for the year ended 31 December 2016 and to consider dividend payment. It does not contain any financial data or detailed report content but merely announces the upcoming board meeting and its agenda. The document length is only 1325 characters, which is very short and fits the pattern of an announcement rather than a full report. According to the rules, such short announcements about meetings to approve results are best classified as Regulatory Filings (RNS) because they do not contain the actual report or financial data but are regulatory announcements related to corporate governance and reporting schedules.
2017-03-08 English
CONNECTED TRANSACTION - ACQUISITION OF THE ENTIRE EQUITY INTEREST IN HEBEI SHIWEI PHARMACEUTICAL TRADING CO., LTD.
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of the entire equity interest in Hebei Shiwei Pharmaceutical Trading Co., Ltd. by CSPC Pharmaceutical Group Limited. It details the transaction terms, parties involved, consideration, and regulatory implications under the Hong Kong Listing Rules, specifically Chapter 14A concerning connected transactions. The document includes financial figures related to the acquired company but does not present comprehensive financial statements or detailed financial analysis of the acquiring company. It is a formal announcement of a connected transaction and acquisition rather than a full merger filing or detailed financial report. The document length is 9620 characters, which is substantial but the content is focused on the acquisition announcement and related regulatory disclosures. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising, financing activities, or capital structure changes through acquisition.
2017-03-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 February 2017
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 28/2/2017, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share issuances or cancellations. The content focuses on share capital changes and equity movements rather than financial performance or earnings. It is a regulatory filing reporting monthly equity movements, not a full financial report or announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2017-03-01 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2017
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/1/2017, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, or management discussion. The document is a regulatory filing reporting monthly share capital movements, which aligns with a Capital/Financing Update rather than a full financial report or announcement of voting results. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a confident classification.
2017-02-01 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2016
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/12/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements rather than a financial report or announcement of a report. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is sufficient and contains detailed data, not just an announcement or certification, so it is not RPA or RNS.
2017-01-03 English
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND CO-DEVELOPMENT AGREEMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding a product licensing and co-development agreement with Teva Pharmaceuticals. It details the terms of the agreement, including responsibilities, payments, and exclusivity. The document is relatively short (3159 characters) and is an announcement of a business agreement rather than a financial report or regulatory filing. It does not contain financial statements, audit information, voting results, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category related to business agreements and partnerships, which aligns with Regulatory Filings (RNS).
2016-12-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.